Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

NCT01373164 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01373164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01373164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2011
Completion date
December 31, 2016
Enrollment
170 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, neoplasms, pancreatic cancer